Used in the treatment of cancers that overexpress the EGFR receptor, such as non-small cell lung cancer, colorectal cancer, and head and neck cancers. It works by binding to the extracellular domain of EGFR, blocking ligand binding and preventing receptor activation, which inhibits tumor cell proliferation, survival, and metastasis. Matuzumab has been investigated in clinical trials for its ability to enhance the effects of chemotherapy and radiation. It serves as a reference antibody in research and development of biosimilars and immunoassays targeting EGFR.